Document is current
Any future updates will be listed below
-
Authors
Gates, Emer https://orcid.org/0000-0001-8253-3887
Hole, Barnaby
Hayward, Samantha
Chesnaye, Nicholas C.
Meuleman, Yvette
Dekker, Friedo W.
Evans, Marie
Heimburger, Olof
Torino, Claudia
Porto, Gaetana
Szymczak, Maciej
Drechsler, Christiane
Wanner, Christoph
Jager, Kitty J.
Roderick, Paul
Caskey, Fergus
,
-
Funding
Funding for this research was provided by:
ERA-EDTA
Swedish Medical Association
Stockholm County Council ALF
CIMED, Njurfonden
Italian Society of Nephrology
Dutch Kidney Foundation
Young Investigators Grant in Germany
National Institute for Health Research in the UK.
- License Information
-
More Information
Article History
Received: 26 January 2021
Accepted: 28 October 2021
First Online: 11 February 2022
Declarations
:
: Informed written consent was obtained from all participants in this study. This is held centrally by the EQUAL study team. In the UK, which this paper focuses on, ethical approval was provided by the Health Research Authority, National Research Ethics Service, South-West, Central Bristol; Reference number 13/SW/0015. The IRAS project ID for this approval is 118368.
: Informed written consent was obtained from all participants in this study for their medical details to be published. This consent is held nationally by EQUAL study teams.
: Co-author CW is a council member and president elect of the ERA-EDTA and KJ has received grants from ERA-EDTA. CW has received personal fees and/or grants from the following pharmaceutical companies during the conduct of the study: Sanofi, Takeda, Chiesi, Amicus, Idorsia, BoehringerIngelheim, Lilly, MSD, Mundipharma, GlaxoSmithKline, AstraZeneca, Bayer, Reata, Akebia and Triceda.
